Tianjin Pharmaceutical Group announced on the evening of November 18 that its subsidiary, Tianjin Pharmaceutical Group Co., Ltd., has obtained a registration certificate from the Ministry of Health of the Republic of Panama for Methylprednisolone Sodium Succinate for Injection. This milestone signifies that the drug is approved for manufacturing and marketing in the Republic of Panama. Following the product's registration certificate from the Ministry of Health of the Dominican Republic in April this year, this latest approval marks another significant achievement in the company's expanding international presence.
Methylprednisolone Sodium Succinate for Injection is a corticosteroid medication primarily used for anti-inflammatory therapy, immunosuppressive treatment, managing hematological diseases and cancers, and treating shock.Tianjin Pharmaceutical Group Co., Ltd. submitted its registration application to the Ministry of Health of the Republic of Panama in 2024 and received approval, securing the registration certificate in November 2025. According to the IQVIA database, the global sales of Methylprednisolone injectable formulations were $526 million in 2023 and $521 million in 2024.
Tianjin Pharmaceutical Group stated that "the approval of Methylprednisolone Sodium Succinate for Injection from its subsidiary Tianjin Pharmaceutical Group Peace Co., Ltd. by the Ministry of Health of the Republic of Panama will open new opportunities for its preparation business to expand into the Panamanian market and further advance the company's international strategic layout."
Tianjin Pharmaceutical Group has established an extensive and solid market foundation. The company actively expands its overseas operations, having built a notable presence in international markets through participation in global exhibitions, technical collaborations, and market promotion initiatives.
In the active pharmaceutical ingredient (API) sector, the company is committed to maintaining its market share for key products across Europe, Asia, and the Americas. It has proactively responded to market fluctuations caused by U.S. tariff policies to ensure stable supply, achieving sales growth for multiple products despite challenging conditions. Meanwhile, it is deeply exploring the potential of new products and emerging markets, successfully opening up new growth pathways.
In the finished dosage form (preparation) sector, the company leverages its core products as competitive drivers and treats the global market as a strategic chessboard. Through precise market strategies and efficient business execution, it has strengthened its position in key markets while achieving comprehensive breakthroughs in emerging markets.
According to the 2025 interim report, the company's overseas revenue reached RMB 515 million in the first half of the year, accounting for approximately one-third of its total core business revenue. This demonstrates the strategic results of its long-term commitment to the international market. Tianjin Pharmaceutical Group's global expansion journey—from consolidating its strengths in APIs to achieving breakthroughs in emerging markets like Panama with its preparations—reflects its steady progress from technological advancement to market development.

Reference: https://finance.eastmoney.com/a/202511193568642624.html